Investigating COVID-19 severity based on serum levels of vascular endothelial growth factor (VEGF)
M. Samareh Fekri (Kerman, Islamic Republic of Iran), E. Barfzade (Kerman, Islamic Republic of Iran), A. Shafahi (Kerman, Islamic Republic of Iran), M. Farokhnia (Kerman, Islamic Republic of Iran), F. Karami Robati (Kerman, Islamic Republic of Iran), S. Movahedinia (Kerman, Islamic Republic of Iran), S. Dabiri (Kerman, Islamic Republic of Iran)
Source: International Congress 2022 – Respiratory inflammation and the pulmonary consequences of COVID-19
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Samareh Fekri (Kerman, Islamic Republic of Iran), E. Barfzade (Kerman, Islamic Republic of Iran), A. Shafahi (Kerman, Islamic Republic of Iran), M. Farokhnia (Kerman, Islamic Republic of Iran), F. Karami Robati (Kerman, Islamic Republic of Iran), S. Movahedinia (Kerman, Islamic Republic of Iran), S. Dabiri (Kerman, Islamic Republic of Iran). Investigating COVID-19 severity based on serum levels of vascular endothelial growth factor (VEGF). 4274
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|